The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golovina, T. N.
Right arrow Articles by Eisenlohr, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golovina, T. N.
Right arrow Articles by Eisenlohr, L. C.
The Journal of Immunology, 2005, 174: 2763-2769.
Copyright © 2005 by The American Association of Immunologists

The Impact of Misfolding versus Targeted Degradation on the Efficiency of the MHC Class I-Restricted Antigen Processing1

Tatiana N. Golovina, Susan E. Morrison and Laurence C. Eisenlohr2

Department of Microbiology and Immunology, Jefferson Medical College and Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Evidence suggests that most epitopes presented by MHC class I molecules are derived from those newly synthesized proteins that are defective due to errors during manufacture. We examined epitope production from model cytosolic and exocytic proteins modified in various ways. Substrates containing a degradation targeting sequence demonstrated very rapid turnover and enhanced epitope production, as was the case for substrate retargeted from endoplasmic reticulum to cytosol. For less radical alterations, including point mutation and deletion and elimination of glycosylation sites, despite detectable changes in folding, half-life was only moderately decreased and there were no significant increases in epitope production. Puromycin, which causes premature termination of protein synthesis, also had no impact upon epitope production. It appears that most defective proteins are not rapidly dispensed with and the targeting of most nascent proteins for Ag processing is not tied to quality control.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
A number of recent publications conclude that the peptides presented by MHC class I molecules to CD8+ T lymphocytes are derived from nascent polypeptides that have not assumed proper conformation due to errors during transcription, translation, and/or folding (1, 2, 3, 4). This is intuitively appealing because such flawed proteins, termed DRiPs (defective ribosomal products) (5), should be targeted to the cellular degradation machinery, including the multicatalytic proteasome, that has been demonstrated to play a critical role in class I-restricted peptide generation (6, 7, 8). This notion has been tested in many different systems that compare the presentation of wild-type Ag with variants designed to enhance the rate of degradation. Strategies include mutation to induce misfolding (9, 10), relocation to a different subcellular compartment (11, 12), and attachment of a degradation signal (degron) (4, 11, 12, 13, 14, 15, 16). However, the second two strategies, while almost universally demonstrated to enhance peptide generation, may not accurately predict the fates of DRiPs because degron-mediated degradation is a highly precise and rapid process. At the same time, errors in subcellular mistargeting appear to be rare (17, 18). To determine the relative influence of these and other modifications upon epitope supply, we assessed the production of two distinct epitopes incorporated into two model Ags targeted to the cytosol and to the endoplasmic reticulum (ER).3


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Chemicals

General chemical supplies were obtained from Sigma-Aldrich. Molecular biology reagents were obtained from New England Biolabs. Isotopes were purchased from ICN Biomedicals and lactacystin was purchased from Boston Biochemicals. Monoclonal anti-nucleoprotein (NP) Abs (clones H16-L10-4R5 and H19-S24-4) were provided by Dr. W. Gerhard (Wistar Institute, Philadelphia, PA), anti-Tac hybridoma (clone 7G7B6) were obtained from American Type Culture Collection; monoclonal anti-hemagglutinin (HA) tag Abs (clone 12CA5) were purchased from Roche Diagnostic Systems. PCR primers were synthesized at the Kimmel Cancer Center Nucleic Acid Facility (Philadelphia, PA).

Cell lines and mice

L-Kd (L929 transfected with H-2Kd) and L-Kb (L929 transfected with H-2Kb) were maintained in DMEM with 5% FBS. Six- to 8-wk-old female inbred BALB/c (H-2d) and C57BL/6 (H-2b) mice were obtained from Taconic Farms or The Jackson Laboratory and maintained in the Thomas Jefferson University Laboratory Animal Facilities (Philadelphia, PA).

Viruses

Generation of the triple tandem HA-tag and addition of OVA257–264 epitope with five flanking amino acids on both sides to NP13–498-based Ags was done by the two-step PCR using consequent primers: CCTGACTATGCGGGGTCATACCCATACGATGTTCCAGATTACGCTGGATCTCTTGAGCAGCTTGAGAGT and GCGTCGACCACCATGGCTAGCTATCCCTATGACGTACCCGACTATGCAGGCTCGTATCCTTATGACGTGCCTGACTATGCGGGGTCA.

Val280 and Tyr281 substitution with arginines (NP13–498/RR) was done by two-step PCR using two mutation primers: 5'- CTGCCTGCCTGTAGAAGAGGGCCCGCCGTA and 3'-TACGGCGGGCCCTCTTCTACAGGCAGGCAG as described earlier (19). NP13–498/{Delta} was made by creating ClaI site using primer CCATCGATCCTTTCAGACTGCTTCAAAACAGCC allowing substitution of the BstB1/NotI fragment of HA-tagged NP13–498 with ClaI/NotI fragment resulting in removal of 144 bp.

HA-tagged Tac Ag appended with OVA257–264 epitope with five flanking amino acids on both sides and following the NP147–155 epitope with five flanking amino acids on both sides was made by four-step PCR with the following primers (in order of use): 1)GAATCTTTCGAATGGACCAGTAATT2TGAATGATGCAACTTATCAGAGGACAAGAGCTCTTGTTCGCACCGGAATGGATCCCGAGCTCTGTGACGATGAC; 2)GAGCAGCTTGAGAGTATAATCAACTTTGAAAAACTGACTGAATGGACCAGTAATTTGAATGATGC; 3)TATGACGTACCGGACTATGCCGGTAGCTACCCATACGATGTTCCAGATTACGCCGGCTCTCTTGAGCAGCTTGAGAGTATA, and CTGCAGGCTTCGAATACCCGTATGATGTCCCCGACTACGCAGGGTCGTATCCTTATGACGTACCGGACTAT for regular Tac, allowing substitution of a BstB1/PstI fragment, or ACGCGTCGACCACCATGTACCCGTATGATGTCCCCGACTACGCAGGGTCGTATCCTTATGACGTACCGGACTAT for Tac targeted to the cytosol.

Addition of the ubiquitin (Ubi) moiety and changing the N-terminal amino acid to Arg was done using the primer CTAGCTAGCCCTGCCACCTCTCAGTCTTAAGACCAGGTGCAGGG adding Arg to the C terminus of Ubi followed by the NheI site. All HA tags were constructed such that that they contained an NheI site immediately after the ATG initiation codon thus allowing for substitution with Ubi-Arg using SalI/NheI. The genes were cloned into the modified pSC11 plasmid, containing {beta}-glycosidase gene. Sequencing, using {beta}-cyanoethyl phosphoramidities chemistry (Applied Biosystems) and conducted by the Kimmel Cancer Institute Nucleic Acid Facility, confirmed the integrity of each construct. Recombination into vaccinia virus (vac) and titration of vac (in duplicate) was conducted as described (20).

Flow cytometric analysis

L-Kb cells were infected for 1 h at 37°C with vaccinia recombinants at 10 PFU/cell at a concentration of 106 cells/ml in balanced salt solution containing 0.1% BSA. After 1 h, RPMI 1640 plus 10% FBS media was added and the cells were incubated for additional time. Aliquots were removed every hour and stained for Kb/OVA257–264 complexes on the surface with 25-D1.16 mAbs specific for Kb/OVA257–264 complex (obtained from A. Porgador, University of Ben-Gurion, Beer-Shiva, Israel) and FITC-labeled goat anti-mouse Abs (Vector Laboratories), and then were fixated in 2% solution of paraformaldehyde (Electron Microscopy Sciences) in PBS.

In the experiments with puromycin, 200 µM puromycin was added after 1 h of infection and removed after 20 min of incubation; the cells were then washed twice with RPMI and resuspended in RPMI. The infection then proceeded, and the aliquots were removed and stained as earlier described.

When needed, permeabilization of the cells was performed as previously described (21): the cells were first fixated in 4% solution of formaldehyde in PBS for 10 min, washed three times with PBS, then permeabilized in 2 mg/ml n-octyl-{beta}-D-glucopyranoside (Calbiochem) for 10 min, and washed three times before staining.

CTL assay

Epitope-specific TCD8+ were derived from C57BL/6 or BALB/c mice, respectively, as described elsewhere (22). Briefly, mice were immunized by i.p. injection of 5 x 106 PFU of a vac expressing the isolated OVA257–264 epitope in the case of C57BL/6, or a vac expressing the isolated NP147–155 epitope in the case of BALB/c mice. After at least 2 wk, spleens from appropriate mice were harvested, and one-third of the cells were infected with A/PR/8/34 influenza virus or WSN/33-Ova influenza virus with OVA257–264 epitope incorporated in the virus neuraminidase stalk (constructed by Dr. M. Castrucci and provided by D. Topham, University of Rochester, Rochester, NY) for restimulation. Secondary cultures were incubated at 37°C/6% CO2 for 6–7 days before harvesting for effector population. CTL assays were performed as previously described (20). L-Kd or L-Kb cells were used as APCs for H-2Kd- or H-2Kb-restricted responses, respectively. APC were infected for 1 h at 37°C with vaccinia recombinants at 10 PFU/cell at a concentration of 107 cells/ml in balanced salt solution containing 0.1% BSA. After 1 h, 2 ml of RPMI 1640 plus 10% FBS were added and the cells were incubated for another 50 min with rotation before 5 µg/ml brefeldin A was added and the cells were rotated another 10 min. When needed, puromycin was added for 20 min following an hour of infection and then the cells were washed three times with PBS. The cells were then pelleted and resuspended with 50 µl/106 cells of RPMI 1640 with 10% FCS containing 50 µCi of Na51CrO4 (ICN) and incubated for 1 h at 37°C. APC were then washed three times with PBS and resuspended in RPMI 1640 plus 10% FBS and combined with CTL populations in round-bottom plates at 104 cells/well. APCs and CTL were coincubated for 4 h at 37°C before 100 µl of supernatants were collected, mixed with the same amount of OptiPhase SuperMix scintillation liquid, and counted in a 1450 Microbeta liquid scintillation and luminescence counter. The data are presented as percentage of specific 51Cr release, defined as 100 x ((experimental cpm – spontaneous cpm)/(total cpm – spontaneous cpm)).

Metabolic labeling and immunoprecipitation

Metabolic labeling and immunoprecipitation were performed as previously described (20). Gels were dried and exposed to LE Storage Phosphor Screen (Molecular Dynamics), and the luminescence was measured using Typhoon 8600 Variable Mode Imager and analyzed using Image Quant software.

Western blotting

Laemmli SDS-PAGE and transfer to nitrocellulose membrane were performed as previously described (23). The protein bands were visualized by consequent incubating with anti-HA Abs (1 µg/ml) (Roche), HRP conjugated goat anti-mouse Abs dilution 1/10,000 (Vector Laboratories) and LumiGLO Chemiluminescent Substrate System (Kirkegaard & Perry Laboratories) with subsequent autoradiography.

Proteinase K treatment

The cells were metabolically labeled as described elsewhere (20), lysed in the lysis buffer (0.01M Tris-HCl, pH 7.5, 0.14 M NaCl, 0.5% Nonidet P-40), and the constructs were immunoprecipitated with anti-HA Abs immobilized on rProtein A-agarose beads (RepliGen). The gel slurries were washed once with the lysis buffer and three times with PBS. The samples were placed on ice, and 1 µg/ml proteinase K was added to the gel slurries with immobilized Ags. Aliquots were removed at indicated times and 5 mM PMSF was added to stop the reactions. The slurries were washed then once with PBS and boiled 5 min in the Laemmli buffer. Proteolytic fragments were separated by SDS-PAGE in 12% gels and visualized by autoradiography.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Generation and biochemical characterization of the cytosolic and exocytic Ags and their variants—folding and half-lives

NP from influenza virus A/PR/8/34 depleted of the twelve N-terminal amino acids that target it to the nucleus (NP13–498) was used as a model cytosolic Ag. The loss of amino acids 1–12 does not impact folding as demonstrated by continued reactivity with a large panel of anti-NP mAbs nor is there an effect upon presentation efficiency (data not shown). The {alpha}-chain of human IL-2R (Tac Ag) was used as a model glycoprotein that would be subject to quality control within the ER. Both groups of model Ags were appended with an HA-tag in triplicate which does not disturb folding of the core proteins (data not shown) and allows for the retrieval of Ag independent of its folding state. Each Ag was further engineered to contain the same two epitopes: H-2Kb-restricted OVA257–264 and H-2Kd-restricted NP147–155 (Fig. 1). These epitopes were chosen because, for all earlier constructs as well as those used here, they demonstrate strikingly different sensitivity to proteasome inhibitors; while OVA257–264 presentation is profoundly inhibited by proteasome inhibitors, NP147–155 presentation is either unchanged or increased depending upon context (16, 19, 22). The basis for this latter presentation phenotype is the presence of both chymotryptic-like and tryptic-like proteasomal cleavage sites within NP147–155 sequence (TYQRTRALV) (19). This suggests the possibility, supported by preliminary data (E. J. Wherry, T. N. Golovina, S. E. Morrison, G. Sinnataumby, M. S. McElhaugh, L. C. Eisenlohr, manuscript in preparation) that nonproteasomal proteases (24, 25, 26) are involved in the generation of NP147–155.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 1. Model Ags based on NP13–498 (targeted to the cytosol) and on Tac (targeted to the ER).

 
Cytosolically targeted influenza virus NP (NP13–498) was altered to induce misfolding in two ways: 1) substitution of Val280 and Tyr281, located in the center of a hydrophobic domain spanning residues 250–301, with arginine residues (NP13–498/RR), a manipulation based upon previous reports that similar changes decrease stability (27, 28); and 2) deletion of the entire NP250–301 hydrophobic domain (NP 13–498/{Delta}). The constructs were incorporated into vac, which allow for expression in a wide range of cell lines.

Compared with NP13–498, NP13–498/RR, and NP13–498/{Delta} are more rapidly digested by proteinase K, and the digestion products are different for all three (Fig. 2A), indicating altered folding states. This is also apparent when comparing immunoprecipitation of the constructs with the conformation-independent anti-HA mAb vs the conformation-dependent anti-NP mAb H19-S24-4; precipitation of NP13–498/RR with H19-S24-4 is clearly impaired compared with NP13–498 while NP13–498/{Delta} does not interact with this Ab at all (Fig. 2A). The protein was also targeted for programmed degradation by replacing the initiating methionine with arginine and preceding the construct with a Ubi moiety that is posttranslationally removed by Ubi C-terminal hydrolase (29). According to the N-end rule (30), an arginine residue at the N terminus constitutes a degron that mediates rapid, Ubi-dependent degradation. As anticipated by published results (11), Ubi-Arg-NP13–498 was completely degraded within several min (Fig. 2E, discussed below). This precluded analysis of its folding using proteinase K sensitivity assay. However, immunoprecipation analysis, demonstrating relatively weak interaction with the anti-NP Ab H19-S24-4, indicates that this construct is also misfolded (Fig. 2A).



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 2. Folding status and stability of the model Ags. A, Proteinase K sensitivity of NP13–498 and its derivatives. Left panel, Fluorograph of fragments separated by SDS-PAGE. Right panel, Phosphoroimager quantitation of relative amounts of proteins left at certain chase time points. Comparison of immunoprecipitation of NPs with anti-HA-tag and anti-NP H19-S24-4 mAbs: lane 1, control virus; lane 2, NP13–498; lane 3, NP13–498RR; lane 4, NP13–498{Delta}; lane 5, Ubi-Met-NP13–498; and lane 6, Ubi-Arg-NP13–498. B, Proteinase K sensitivity of Tac Ags. Left panel, Fluorograph of fragments separated by SDS-PAGE. C, Comparison of immunoprecipitation of Tac and TacGlu- with anti-HA-tag and anti-Tac Abs. Top panel, Fluorograph of proteins separated by SDS-PAGE. Bottom panel, Phosphoroimager quantitation of relative amounts of proteins left at certain chase time points. D, Immunoprecipitation of Tac and cytoTac with conformation insensitive (anti-HA-tag) and conformation sensitive (anti-Tac clone 7G7B6) Abs. E, Stability of the model Ags. F, Surface expression of Tac Ags. Flow cytometry, staining with anti-Tac 7G7B6 Abs.

 
The Tac-based Ag was initially modified in three ways. First, we mutated both sites of asparagine-linked glycosylation because sugar moieties play an important role in the quality control of glycoproteins (31). Although TacGlu- can be immunoprecipitated by a conformation-dependent anti-Tac Ab, the quantity precipitated diminishes with longer chase periods following metabolic labeling. This is in contrast to precipitation with the conformation-insensitive anti-HA-tag Ab that declines at a slower rate, indicating a deterioration of the structure over time (Fig. 2C). Second, the signal peptide was removed, forcing delivery to the cytosol (cytoTac), a location lacking the environment and machinery necessary for the proper folding of this protein. A similar modification to influenza HA (11) results in profound misfolding and instability. As expected, cytoTac is rapidly digested by proteinase K (results not shown) and is precipitable with the anti-HA-tag Ab but not the conformation sensitive anti-Tac 7G7B6 Ab (Fig. 2D). Third, we used a modification described by Bonifacino et al. (32), in which L10 within the transmembrane domain was substituted with arginine (TacR10). Although charged residues in transmembrane domains often serve to drive oligomerization, in the case of a monomeric protein such as Tac, such residues usually constitute a degradation signal (32, 33). The folding of TacR10 appears to be similar to that of wild-type Tac because they are essentially identical in terms of proteinase K sensitivity and digestion patterns (Fig. 2B).

The misfolded NP-based constructs (NP13–498/RR and NP13–498/{Delta}) had only moderately decreased half-lives (1.8 and 2 h, respectively) compared with 2.8 h for NP13–498, while the half-life of Ubi-Arg-NP13–498 is dramatically lower (10 min) (Fig. 2E, top panel). Indeed, it has been reported that N-end rule substrates can be targeted for degradation even before translation has been completed (34). Among the Tac-based constructs, the half-life of TacGlu– was identical to that of wild-type Tac (2.3 h). Despite its unstable folding noted above, this construct passes quality control within the ER and is transported to the cell surface (Fig. 2F). TacR10 has a moderately decreased half-life of 30 min which is sufficient for the proper folding of its extracellular domain (Fig. 2E, bottom panel) but, as anticipated (32), this construct is not transported to the cell surface (Fig. 2F), and is likely targeted to the cytosol for degradation (18, 35, 36, 37, 38). CytoTac was most rapidly degraded, with a half-life of ~15 min (Fig. 2E, bottom panel). Thus, among the described model Ags, only the variant with profound misfolding due to relocation within the cell (cytoTac), and those containing degrons (Ubi-Arg-NP13–498 and TacR10) were rapidly degraded. The other variants, more representative of the errors that would arise during transcription, splicing, or translation are degraded at a rate not much faster than that of wild-type, a remarkable fact taking into consideration that these changes do significantly impact the protein structure.

Finally, it was important to determine the degree to which defective products are made during the expression of the wild-type proteins. If rapidly degraded, the products of such errors might be undetectable by the analyses shown thus far. Most importantly, if such products are abundant, then the imposed changes might affect a relatively minor increase in the total amount of defective proteins available for class I processing. To this end, we used an approach similar to that taken by others (3). Cells were infected with the various recombinant viruses in the presence or absence of the proteasome inhibitor lactacystin. Following lysis, relative steady state levels were determined by PAGE followed by Western blotting and staining with anti-HA Abs (Fig. 3). Addition of lactacystin revealed that some truncated polypeptides were produced during biosynthesis of the wild-type NP13–498 but not a wild-type Tac. These truncated products would appear to have little significance in terms of epitope production as addition of a degradation signal to NP13–498 does not result in production of more truncated products, yet, as shown below, this modification greatly enhances epitope supply. The same is true for the Tac Ags; with the difference that in contrast to the stable Tac, destabilized Tac derivatives showed a ladder pattern consistent with multiubiquitylation (Fig. 3).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 3. Effect of lactacystin on the expression and degradation of the model Ags. The cells were infected with the indicated vac for 4 h with and without 50 µM lactacystin and then lysed. The lysates were separated by SDS-PAGE, Western blotted, and stained with anti-HA-tag Abs.

 
Impact on epitope presentation—the cytosolic NP-based constructs

OVA257–264 epitope presentation was assessed in two ways: surface staining with Abs specific for OVA257–264/H-2Kb complexes (clone 25-D1.16) and 51Cr release cytotoxic assay in which surface complexes were limited through the use of brefeldin A treatment (39, 40). Staining with OVA257–264/Kb-specific Abs revealed that the first OVA257–264/H2-Kb complexes from either NP13–498, NP13–498/RR, or NP13–498/{Delta} were detectable after 3 h of infection while the OVA257–264/H2-Kb complexes from Ubi-Arg-NP13–498 are readily apparent within the first 2 h of infection (Fig. 4A). 51Cr release assay results closely correlated with the Ab staining results (Fig. 4B).



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 4. OVA257–264 and NP147–155 presentation in different contests. A and D, Staining of surface OVA257–264/Kb complexes with 25-D1.16 Abs. B and E, OVA257–264 presentation, 51Cr release assay. C and F, NP147–155 presentation, 51Cr release assay.

 
NP147–155 epitope presentation was evaluated by the 51Cr release assay only as NP147–155/H2-Kd-specific Ab is not available. Despite the fact that this epitope differs radically from OVA257–264 in being indifferent to or enhanced by proteasome inhibitor (16, 19, 22), its presentation pattern was essentially identical (Fig. 4C); the rapidly degraded, degron-containing Ubi-Arg-NP13–498 generated the highest levels of epitope while the misfolded versions of NP13–498 were indistinguishable in this regard.

Impact on epitope presentation—the exocytic Tac-based constructs

Within the Tac group of model Ags, the trend was similar in that only those versions that are profoundly unstable due to circumstances beyond simple misfolding allow for greater epitope production. However, after this first level of assessment, results were less straightforward. Elimination of N-linked glycosylation had no impact on presentation of either epitope (Fig. 4, D and F), in line with the lack of effect upon degradation rate. The appearance of OVA257–264/H2-Kb complexes from cytoTac and TacR10 was more rapid compared with the wild-type Tac construct, although after 4 h of infection the number of surface complexes was appreciably lower in the case of cytoTac compared with TacR10 (Fig. 4D). Given the extreme misfolded state of cytoTac, one explanation for its lower contribution of epitope could be that it is subject to degradation by other cellular proteases that might diminish the amount of substrate for "productive" proteasomal degradation. However, addition of various individual protease inhibitors of different specificities or protease inhibitor mixtures does not enhance OVA257–264 presentation from cytoTac at later time points (data not shown). Therefore, we considered the possibility that the cellular machinery associated with degron-mediated destruction produces epitope more efficiently than the machinery associated with the destruction of misfolded proteins, however profound the degree of misfolding. If true, then addition of a degron to cytoTac should enhance epitope production. To test this, we converted cytoTac to an N-end rule substrate by substituting its N-terminal Met with Arg. Ubi-Arg-cytoTac became the most unstable construct of all those tested (data not shown), but the modification increased OVA257–264 production only slightly (Fig. 4D). Thus, the efficient generation of epitope from TacR10 cannot be explained by degradation rate or qualitative aspects of degron-mediated destruction.

For OVA257–264 presentation, results were similar in 51Cr-release assay although the differences were not so prominent (Fig. 4E). Interestingly, the pattern of presentation for the NP147–155 epitope was distinct, with appreciably more efficient generation of the epitope from all three modified Tac variants (Fig. 4F) despite considerable differences in degradation rates.

Impact of premature translation termination on epitope production

It has been shown by others that brief termination of protein synthesis with puromycin increases the presentation of influenza matrix 58–66 epitope in low molecular protein-deficient cells, suggested by the authors to be due to an increase in the amount of defective products available for processing (9). Following very similar experimental conditions, we investigated the impact of puromycin on presentation of our epitopes from various constructs. Consistent with results shown above, though puromycin pretreatment induced a number of shorter products (Fig. 5A), it did not increase the level of OVA257–264 or NP147–155 presentation in either context (Figs. 5, B and C); rather, it slightly decreased the level of presentation from the more rapidly degraded constructs. Under similar experimental conditions Gileadi et al. did observe an increase in the presentation of epitope 58–66 from influenza virus Matrix protein (9), but it was in a different system, namely, in low molecular protein-deficient cells, and matrix 58–66 epitope was not presented in these cells if expressed in the contest of wild-type matrix protein.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 5. Effect of brief puromycin treatment on OVA 257–264 presentation (25-D1.16 staining) and on NP147–155 presentation (cytotoxic assay). The arrow indicates puromycin treatment. A, Western blot and anti-HA-tag staining of the cell lysates. B, OVA257–264 presentation. C, NP147–155 presentation.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The initial goal of this project was to test the prediction that misfolding of our constructs would differentially affect the presentation of NP147–155 and OVA257–264 based upon the opposite impact that proteasome inhibitors have on their production and the prevailing models. Thus, if misfolding leads to enhanced proteasome-dependent degradation, we anticipated increased presentation of OVA257–264 but not NP147–155. However, in almost all cases, misfolding, either through radical amino acid substitutions, substantial deletion, or puromycin treatment had no impact on generation of either epitope. Only through addition of a degron or retargeting from the exocytic pathway to the cytosolic pathway was epitope production consistently enhanced. This agrees with the notion proposed by others that defective proteins are not turned over immediately. Rather, the folding machinery of the cell makes several attempts at creating a functional protein, allowing for structural solutions that can compensate for some mutations (41) and possibly providing a holding area for defective proteins when higher priority substrates, such as those containing degrons, tax the degradation machinery. Although cytoTac does not contain a degron, an exocytic protein delivered to the cytosol, with limited possibilities of disulfide bonding and glycosylation, may be quickly recognized by the quality control machinery as irreparable and, with the lack of even subdomain folding, immediately targeted for disposal. This notion is supported by the work of Wong et al. who evidently observed that only extensive rearrangement of HIV gag or employment of the N-end rule resulted in enhanced degradation and increased epitope production. Less radical changes were not destabilizing, and epitope production was not increased (10). Thus, it appears that if a protein is substantially defective it can be targeted for rapid degradation without a degron. How such proteins are targeted and the frequency with which they arise can only be answered with further study. Obviously our sample size, although representing two distinct types of proteins, is relatively limited.

Assuming, for the sake of this discussion, that the types of processing substrates represented by cytoTac are relatively rare, how can our findings be reconciled with the observation that nascent proteins are the major source of class I-restricted peptide (3)? It has been demonstrated that both the degradation and folding machineries of the cell can access nascent polypeptides before termination of translation (34, 42). Thus there is a competition for any nascent prefolded protein between the folding and degradation machineries of the cell. We propose that epitopes are derived from the cases, likely rare, where the degradation machinery prevails. The ultimate success of a protein in terms of folding would have no bearing on this competition, explaining why most of our point mutations and deletions have no impact on epitope supply. In contrast, the degron-containing polypeptides are almost uniformly targeted for destruction either during or after translation independent of folding state.

Based upon much of the work reported here, appending a degron to an Ag may seem a reasonable strategy for enhancing TCD8+ activation, but the task is clearly more complex. The most rapidly degraded protein (Ubi-CytoTac) of the group we tested does not produce the highest level of epitope, indicating qualitative aspects of Ag processing that remain poorly understood. In addition, as has been shown recently, (10, 43), the relative epitope production from two versions of an Ag does not predict the relative level of T cell response, due to nebulous in vivo phenomena such as cross-presentation. Indeed, preliminary in vivo experiments with the constructs described here indicate that efficiency of epitope production is not predictive of immunogenicity (T. N. Golovina, unpublished observations). This contrasts with earlier studies where we modulated expression levels of a single model Ag, and under such circumstances epitope production is essentially predictive of the magnitude of the TCD8+ response (44). The collective data indicate that protein context is an important determinant of both epitope production and immunogenicity, and that these two properties are differentially impacted. A deeper understanding of this disconnect should contribute significantly to the rational engineering of Ags to optimize TCD8+ responses.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Acknowledgments
 
We thank Steven Meschino and Michael McElhaugh for excellent technical assistance and Drs. Judith Frydman and Mark Hochstrasser for helpful discussions.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants to L.C.E. from the National Institutes of Health (AI39501) and the Leukemia and Lymphoma Society (1121-00). T.G. was supported by National Institutes of Health Training Grant 5-T32-CA09683. Back

2 Address correspondence and reprint requests to Dr. Laurence C. Eisenlohr, Thomas Jefferson University, Bleumle Life Sciences Building, Room 706, 233 South 10th Street, Philadelphia, PA 19107. E-mail address: L_Eisenlohr{at}mail.jci.tju.edu Back

3 Abbreviations used in this paper: ER, endoplasmic reticulum; NP, nucleoprotein; HA, hemagglutinin; Ubi, ubiquitin; vac, vaccinia virus. Back

Received for publication October 15, 2004. Accepted for publication December 20, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Khan, S., R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, M. Groettrup. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167:4801.[Abstract/Free Full Text]
  2. Reits, E. A., J. C. Vos, M. Gromme, J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404:774.[Medline]
  3. Schubert, U., L. C. Anton, J. Gibbs, C. C. Norbury, J. W. Yewdell, J. R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770.[Medline]
  4. Princiotta, M. F., D. Finzi, S. B. Qian, J. Gibbs, S. Schuchmann, F. Buttgereit, J. R. Bennink, J. W. Yewdell. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18:343.[Medline]
  5. Yewdell, J. W., L. C. Antón, J. R. Bennink. 1996. Defective ribosomal products (DRIPs): a major source of antigenic peptides for MHC class I molecules?. J. Immunol. 157:1823.[Abstract]
  6. Rock, K. L., A. L. Goldberg. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17:739.[Medline]
  7. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761.[Medline]
  8. Yang, B., Y. S. Hahn, C. S. Hahn, T. J. Braciale. 1996. The requirement for proteasome activity in class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J. Exp. Med. 183:1545.[Abstract/Free Full Text]
  9. Gileadi, U., H. T. Moins-Teisserenc, I. Correa, B. L. Booth, Jr, P. R. Dunbar, A. K. Sewell, J. Trowsdale, R. E. Phillips, V. Cerundolo. 1999. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J. Immunol. 163:6045.[Abstract/Free Full Text]
  10. Wong, S. B., C. B. Buck, X. Shen, R. F. Siliciano. 2004. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 173:3073.[Abstract/Free Full Text]
  11. Townsend, A., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar, D. Boyle, S. Chan, G. Smith. 1988. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168:1211.[Abstract/Free Full Text]
  12. Tobery, T. W., R. F. Siliciano. 1997. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185:909.[Abstract/Free Full Text]
  13. Grant, E. P., M. T. Michalek, A. L. Goldberg, K. L. Rock. 1995. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155:3750.[Abstract]
  14. Sijts, A. J., I. Pilip, E. G. Pamer. 1997. The Listeria monocytogenes-secreted p60 protein is an N-end rule substrate in the cytosol of infected cells: implications for major histocompatibility complex class I antigen processing of bacterial proteins. J. Biol. Chem. 272:19261.[Abstract/Free Full Text]
  15. Tobery, T., R. F. Siliciano. 1999. Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J. Immunol. 162:639.[Abstract/Free Full Text]
  16. Antón, L. C., H. L. Snyder, J. R. Bennink, A. Vinitsky, M. Orlowski, A. Porgador, J. W. Yewdell. 1998. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160:4859.[Abstract/Free Full Text]
  17. Schatz, G., B. Dobberstein. 1996. Common principles of protein translocation across membranes. Science 271:1519.[Abstract]
  18. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, C. L. Slingluff, Jr, J. Shabinowitz, D. F. Hunt, V. H. Engelhard. 1998. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37.[Abstract/Free Full Text]
  19. Yellen-Shaw, A. J., E. J. Wherry, G. C. Dubois, L. C. Eisenlohr. 1997. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol. 158:3227.[Abstract]
  20. Bullock, T. N. J., L. C. Eisenlohr. 1996. Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J. Exp. Med. 184:1319.[Abstract/Free Full Text]
  21. Sumaroka, M. V., I. S. Litvinov, S. V. Khaidukov, T. N. Golovina, M. V. Kamraz, R. L. Komal’eva, T. M. Andronova, E. A. Makarov, V. A. Nesmeyanov, V. T. Ivanov. 1991. Muramyl peptide-binding sites are located inside target cells. FEBS Lett. 295:48.[Medline]
  22. Golovina, T. N., E. J. Wherry, T. N. Bullock, L. C. Eisenlohr. 2002. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J. Immunol. 168:2667.[Abstract/Free Full Text]
  23. Laemmli, U. K.. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.[Medline]
  24. Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J. W. Drijfhout, J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495.[Medline]
  25. Goldberg, A. L., P. Cascio, T. Saric, K. L. Rock. 2002. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39:147.[Medline]
  26. Del-Val, M., D. Lopez. 2002. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD8+ T lymphocytes. Mol. Immunol. 39:235.[Medline]
  27. Dao-pin, S., D. E. Anderson, W. A. Baase, F. W. Dahlquist, B. W. Matthews. 1991. Structural and thermodynamic consequences of burying a charged residue within the hydrophobic core of T4 lysozyme. Biochemistry 30:11521.[Medline]
  28. Matsumura, M., J. A. Wozniak, D. P. Sun, B. W. Matthews. 1989. Structural studies of mutants of T4 lysozyme that alter hydrophobic stabilization. J. Biol. Chem. 264:16059.[Abstract/Free Full Text]
  29. Jonnalagadda, S., T. R. Butt, B. P. Monia, C. K. Mirabelli, L. Gotlib, D. J. Ecker, S. T. Crooke. 1989. Multiple ({alpha}-NH-ubiquitin)protein endoproteases in cells. J. Biol. Chem. 264:10637.[Abstract/Free Full Text]
  30. Varshavsky, A.. 1992. The N-end rule. Cell 69:725.[Medline]
  31. Ellgaard, L., A. Helenius. 2003. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4:181.[Medline]
  32. Bonifacino, J. S., P. Cosson, N. Shah, R. D. Klausner. 1991. Role of potentially charged transmembrane residues in targeting proteins for retention and degradation within the endoplasmic reticulum. EMBO J. 10:2783.[Medline]
  33. Fayadat, L., R. R. Kopito. 2003. Recognition of a single transmembrane degron by sequential quality control checkpoints. Mol. Biol. Cell. 14:1268.[Abstract/Free Full Text]
  34. Turner, G. C., A. Varshavsky. 2000. Detecting and measuring cotranslational protein degradation in vivo. Science 289:2117.[Abstract/Free Full Text]
  35. Bonifacino, J. S., C. K. Suzuki, R. D. Klausner. 1990. A peptide sequence confers retention and rapid degradation in the endoplasmic reticulum. Science 247:79.[Abstract/Free Full Text]
  36. Wiertz, E. J. H., D. Tortorella, M. Bogyo, J. Yu, W. Mothes, T. R. Jones, T. A. Rapoport, H. L. Ploegh. 1996. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384:432.[Medline]
  37. Hiller, M. M., A. Finger, M. Schweiger, D. H. Wolf. 1996. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 273:1725.[Abstract/Free Full Text]
  38. Tirosh, B., M. H. Furman, D. Tortorella, H. L. Ploegh. 2003. Protein unfolding is not a prerequisite for endoplasmic reticulum-to-cytosol dislocation. J. Biol. Chem. 278:6664.[Abstract/Free Full Text]
  39. Nuchtern, J. G., J. S. Bonifacino, W. E. Biddison, R. D. Klausner. 1989. Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature 339:223.[Medline]
  40. Yewdell, J. W., C. J. Hackett. 1989. Specificity and function of T lymphocytes induced by influenza A viruses. R. M. Krug, Jr, ed. The Influenza Viruses 361. Plenum, New York.
  41. Frydman, J.. 2001. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 70:603.[Medline]
  42. Liao, W., S. C. Yeung, L. Chan. 1998. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum. J. Biol. Chem. 273:27225.[Abstract/Free Full Text]
  43. Norbury, C. C., S. Basta, K. B. Donohue, D. C. Tscharke, M. F. Princiotta, P. Berglund, J. Gibbs, J. R. Bennink, J. W. Yewdell. 2004. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304:1318.[Abstract/Free Full Text]
  44. Wherry, E. J., K. A. Puorro, A. Porgador, L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163:3735.[Abstract/Free Full Text]

Related articles in The JI:

IN THIS ISSUE

The JI 2005 174: 2447-2449. [Full Text]  



This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Ostankovitch, M. Altrich-VanLith, V. Robila, and V. H. Engelhard
N-Glycosylation Enhances Presentation of a MHC Class I-Restricted Epitope from Tyrosinase
J. Immunol., April 15, 2009; 182(8): 4830 - 4835.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al.
Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity
J Natl Cancer Inst, July 2, 2008; 100(13): 950 - 961.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Goldwich, S. S. C. Hahn, S. Schreiber, S. Meier, E. Kampgen, R. Wagner, M. B. Lutz, and U. Schubert
Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation
J. Immunol., January 1, 2008; 180(1): 372 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
E. Caron, R. Charbonneau, G. Huppe, S. Brochu, and C. Perreault
The structure and location of SIMP/STT3B account for its prominent imprint on the MHC I immunopeptidome
Int. Immunol., December 1, 2005; 17(12): 1583 - 1596.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golovina, T. N.
Right arrow Articles by Eisenlohr, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golovina, T. N.
Right arrow Articles by Eisenlohr, L. C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS